

Future Technology Trends


Christina Egan
APHL Annual Meeting
June 2, 2013

Figure from <http://www.globaltort.com/2013>

Speaker Disclosure


The Association of Public Health Laboratories adheres to established standards regarding industry support of continuing education for healthcare professionals. The following disclosures of personal financial relationships with commercial interests within the last 12 months as relative to this presentation have been made by the speaker(s):

Christina Egan: Nothing to disclose
Presentation: Future Technology Trends



Current “State Of The Art Technology” In Public Health Laboratories

In your laboratory, what is the percentage of sections/units (Bact/Virology/TB/Mycology/Parasit) using real-time PCR?



- a) 0-10%
- b) 10-25%
- c) 25-50%
- d) 50-75%
- e) 75-100%

Does your laboratory plan to utilize whole genome sequencing?

- a) Using it currently
- b) Plan to purchase instrument w/in 1 year
- c) Plan to partner with another institution w/in 1 year
- d) Plan to utilize w/in 5 years

0%

■ a) ■ b) ■ c) ■ d)

Is your laboratory using a Mass Spec based system?



0%

a) Have onsite

0%

b) Plan to purchase within 6 months

0%

c) Plan to purchase within 1 year


0%

d) Plan to purchase within 1-3 years

0%

e) Do plan to utilize this technology

10 Year Outlook




<http://www.behance.net/gallery/Marcel-Laverdet-and-Muscle-Fitness-magazine/245648>

2013
APHL
ANNUAL
MEETING &
7TH GOVERNMENT ENVIRONMENTAL
LABORATORY CONFERENCE


In your jurisdiction, what is the % of labs that utilize real-time PCR?

- a) 0%
- b) 1-10%
- c) 10-25%
- d) 25-50%
- e) 50-75%
- f) 75-100%



In your jurisdiction, how many laboratories utilize mass spectroscopy based systems?

- a) 0%
- b) 1-10%
- c) 10-25%
- d) 25-50%
- e) 50-75%
- f) 75-100%




How will these newer technologies impact the PHL?

- Mass Spectroscopy- Will we see a dramatic decrease in isolates coming into the PHL?
- Will this lead to change in testing needs from clinical labs?
- Will we need to change the type of personnel hired in the PHLs?

How will Molecular Technology Impact the PHL?

- Will PHLs be involved in building genomic databases to be used in outbreak analysis, drug resistance, and typing of organisms?
- Will be need to develop consistent policies and guidelines for the use of these technologies in clinical and PHLs?
- Will there be a change in types of specimens/isolates coming into the PHL? Specimen vs. DNA

What should I do with my clicker?

- a) Throw Away
- b) Give to a Friend
-  c) Return to APHL Staff Member at the Door (**AFTER SESSION**)
- d) Put in Back Pocket

0%